Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses.
Sheila Weitzman, Ronald Jaffe
https://pubmed.ncbi.nlm.nih.gov/15547923/Actively Recruiting
Led by The Hospital for Sick Children · Updated on 2025-06-24
400
Participants Needed
15
Research Sites
N/A
Total Duration
Rare histiocytic disorders RHDs are a group of uncommon diseases characterized by an excess of histiocyte cells infiltrating various organs such as the skin, bones, lungs, liver, spleen, and central nervous system. These disorders range from localized forms that may resolve on their own to widespread progressive forms that can be severe or life-threatening. Because these conditions are very rare, there is limited understanding of their causes and the best treatment approaches. Physicians, patients, and caregivers often consult experts due to a lack of clear treatment guidelines, making this research important for improving knowledge and care. This research involves creating an International Rare Histiocytic Disorders Registry IRHDR to collect and analyze detailed clinical, epidemiological, treatment, and survival information from patients diagnosed with various RHDs, including Juvenile xanthogranuloma family, Erdheim-Chester disease, Multifocal Reticulohistiocytosis, Rosai-Dorfman disease, and Malignant Histiocytoses. The registry does not involve any treatment intervention but focuses on gathering information from past and current cases dating back to 1995. It also includes expert pathology reviews and aims to support the development of future treatment guidelines and clinical trials. Participants provide data and consent for their information to be included in this ongoing registry, which will be analyzed approximately yearly over 10 years. The registry collects information on disease presentation, treatments used, and outcomes over time to better understand these disorders and guide future care. The study facilitates research opportunities and may enable linking clinical data with biological studies to uncover causes and potential therapies. Participation involves data sharing rather than receiving treatments, and no costs are associated with enrolling in the registry.
CONDITIONS
International Rare Histiocytic Disorders Registry (IRHDR)
O
Oussama Abla, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Hospital for Sick Children
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) for data collection and consent
Duration - Up to 10 years
Participants with rare histiocytic disorders are enrolled in a registry to collect and analyze clinical, epidemiological, treatment, and survival data over time to better understand the diseases and optimize treatments.
Data collection visits as needed during routine care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Sheila Weitzman, Ronald Jaffe
https://pubmed.ncbi.nlm.nih.gov/15547923/The Hospital for Sick Children
Lead Sponsor